Edwards, David A.,Man, Jonathan C.,Katstra, Jeffrey P.,Clarke, Robert W.
申请号：
AU2012202618
公开号：
AU2012202618A1
申请日:
2012.05.03
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
#$%^&*AU2012202618A120120524.pdf#####ABSTRACT Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
